ARTICLE | Emerging Company Profile
With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers
Bay Area start-up is pursuing therapies targeting biology shared by pediatric and adult cancers
May 22, 2020 12:32 AM UTC
Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make the former a driving force instead of an afterthought.
Incubated by Canaan, Day One Biopharmaceuticals LLC is also funded by Access Biotechnology and Atlas Venture. ...